-
2 weeks ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteXBI and NBI continue to fall more than broader markets By Meredith Durkin Wolfe, Director of ResearchStocks fell again Tuesday, as markets continue to react to tariff policy. The XBI and NBI have lost 17% and 14% since last Friday, March 28, and 11% and 10% since tariffs were announced Wednesday. Their slide outpaces the broader markets, with the S&P500 down 11% since last Friday and 8% since Wednesday.
-
2 weeks ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data BytePreviously a bright spot in 2025 markets, Hong Kong stocks take a sharp downturn By Meredith Durkin Wolfe, Director of ResearchBiopharma stocks listed in Hong Kong fell Monday, following the trendsetting of the U.S. markets on Friday. Of 24 companies with drugs on the market and valuations over US$1 billion at Friday’s close, 17 performed worse that the 13% drop by the Hang Seng Index (HSI). The smallest loss in the group was 8%.
-
2 weeks ago | 
biocentury.com | Meredith Durkin Wolfe
PRESENTATION | Finance1Q25 Wrap: Market backslide hits broad swath of companiesWinners, losers in biotech stock tiers in 1Q25 By Meredith Durkin Wolfe, Director of ResearchApril 4, 2025 10:56 PM UTCLarge-cap biotechs narrowly avoided the downward trajectory of stock markets in 1Q25, treading water with a median gain of 1%. The group, defined as companies that started the year with market capitalizations of $5-$9.9 billion, saw 17 companies gain value and 16 lose value.
-
2 weeks ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteFirst drug for Prader-Willi hyperphagia, first Xolair biosimilar By Meredith Durkin Wolfe, Director of ResearchFDA’s six new product approvals in March included the first drug to treat hyperphagia in Prader-Willi syndrome: Vykat XR diazoxide choline. Soleno Therapeutics Inc. (NASDAQ:SLNO) is launching the ATP-dependent potassium channel (KATP) agonist in April. It will be the company’s first product.
-
3 weeks ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteFDA has at least seven more target action dates coming up in April By Meredith Durkin Wolfe, Director of ResearchFDA’s deadline to complete review of Novavax’s COVID-19 vaccine came and went Tuesday with no response from the agency.
-
4 weeks ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteSeven of 11 $1B+ immunology acquisitions focused on two diseases By Meredith Durkin Wolfe, Director of ResearchBiopharmas cited immunology as the motivation for 11 M&A deals with upfront valuations over $1 billion in 2022-24. Of those, four of the acquired companies had lead products in the rare autoimmune kidney disease IgA nephropathy, while three were testing treatments for inflammatory bowel diseases.
-
1 month ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteAt least eight East-to-West licensing deals outside oncology so far this year By Meredith Durkin Wolfe, Director of ResearchWith Tuesday’s announcement that Hengrui is granting Merck & Co. ex-China rights to an oral small molecule lipoprotein(a) inhibitor, this year has brought at least eight deals where a Chinese company licensed products to a Western company in a therapeutic focus other than cancer. Both Jiangsu Hengrui Pharmaceuticals Co. Ltd.
-
1 month ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteAt nearly $1.7B, Zealand got $300M more than the prior top cash payment By Meredith Durkin Wolfe, Director of ResearchIn this month’s obesity deal for amylin analog petrelintide, Roche paid Zealand more up front than in any other single-product deal since BioCentury began collecting deals data in 2009. The $1.65 billion cash payment is particularly notable because it went to a European biotech, not an established pharma player.
-
2 months ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteTotal newco financing was $8.7 billion, down from $9.1 billion in 2023 By Meredith Durkin Wolfe, Director of ResearchSeed and Series A financings fell to $8.7 billion in 2024 from $9.1 billion in 2023, despite a nearly $4 billion total increase in overall venture financings. While the aggregate amount raised fell 4% last year, there was a 12% decrease in the number of seed and A rounds, following trends towards larger rounds overall.
-
2 months ago | 
biocentury.com | Meredith Durkin Wolfe
DATA GRAPHICS | Data ByteEurope’s share of global biotech venture was 19% in 2024, while China fell to 7% By Meredith Durkin Wolfe, Director of ResearchEuropean biotech companies raised $6 billion in venture funds in 2024, 19% of the $31.3 raised globally. The region’s total grew from $4.6 billion in 2023, which represented 17% of that year’s total, and nearly matched the $6.1 billion raised in 2020. Chinese biotech financings, by contrast, fell for the third year in row.
